6 Results for "

MO7e

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "MO7e" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-10395
CAS No.: 260415-63-2
Purity:  99.12%
Target:  

Bcr-Abl Src

Research Areas:  

Cancer

PD173955 is an orally active inhibitor of Src (IC50= 22 nM), Yes, Abl, ATP and MAP kinases. PD173955 can effectively prevent the mitotic process and has anticancer activity .
loading...
    loading...
Cat. No.: HY-13496
CAS No.: 885692-52-4
Target:  

c-Fms

Research Areas:  

Inflammation/Immunology Cancer

JNJ-28312141 is an inhibitor for colony-stimulating factor-1 receptor (CSF-1R or FMS), with an IC50 of 0.69 nM. JNJ-28312141 inhibits proliferation of BDBM, MV-4-11, M-o7e, TF-1 with an IC50s of 2.6, 21, 41 and 150 nM, respectively. JNJ-28312141 exhibits anti-inflammatory activity in mouse arthritis model .
loading...
    loading...
Cat. No.: HY-177286
CAS No.: 1185279-55-3
Target:  

c-Kit

Research Areas:  

Inflammation/Immunology Cancer

c-Kit-IN-11 (Compound A7) is a c-Kit inhibitor with an IC50 of 76  nM for Mo7e cells. c-Kit-IN-11 can be used for inflammatory like asthma and malignant cancers research .
loading...
    loading...
Cat. No.: HY-13496A
CAS No.: 1149939-55-8
Target:  

c-Fms

Research Areas:  

Inflammation/Immunology Cancer

JNJ-28312141 hydrochloride is an inhibitor for colony-stimulating factor-1 receptor (CSF-1R or FMS), with an IC50 of 0.69 nM. JNJ-28312141 hydrochloride inhibits proliferation of BDBM, MV-4-11, M-o7e, TF-1 with an IC50s of 2.6, 21, 41 and 150 nM, respectively. JNJ-28312141 hydrochloride exhibits anti-inflammatory activity in mouse arthritis model .
loading...
    loading...
Cat. No.: HY-10395R
CAS No.: 260415-63-2
Research Areas:  

Cancer

PD173955 (Standard) is the analytical standard of PD173955 (HY-10395). This product is intended for research and analytical applications. PD173955 is an orally active inhibitor of Src (IC50= 22 nM), Yes, Abl, ATP and MAP kinases. PD173955 can effectively prevent the mitotic process and has anticancer activity .
loading...
    loading...
Cat. No.: HY-135435
CAS No.: 515821-11-1
Target:  

VEGFR PDGFR FGFR

SU10944 is a selective, orally active VEGFR inhibitor, with an IC50 of 6 nM against VEGFR-1, an IC50 of 96 nM and a Ki of 21 nM against VEGFR-2. SU10944 only exhibits weak inhibitory activity against PDGFRβ (IC50 = 1 μM), SCFR (IC50 = 1.58 μM) and FGFR-1 (IC50 = 1.6 μM). SU10944 selectively inhibits VEGFR receptor downstream signaling, neovascularization, vascular permeability, VEGF-mediated tissue factor production, and induces tumor growth delay. SU10944 can be used in research related to diabetic retinopathy, exudative age-related macular degeneration or cancer .
loading...
    loading...